New Cholesterol Guidelines Expand Statin Eligibility to More Than Half of US Adults
Updated guidelines from the American College of Cardiology and American Heart Association now make more than 56% of US adults aged 30 to 79 eligible for statin therapy. The new rules lower the starting age for eligibility from 40 to 30 and introduce a new risk calculator. Doctors say the changes will help catch cardiovascular risk earlier.
More than half of American adults are now eligible for statin therapy under updated cholesterol guidelines released in March 2026 by the American College of Cardiology and the American Heart Association, along with nine other medical associations.
The new guidelines expand the eligible age range from 40-75 to 30-79 years old. Researchers estimate that approximately 56.6% of US adults in that age bracket now qualify for statin therapy, adding roughly 21.5 million people compared to previous standards.
The guidelines also replace the older Pooled Cohort Equations risk calculator with a new tool called the PREVENT-ASCVD calculator. The new calculator estimates both 10-year and 30-year risks of heart attack and stroke, giving doctors a longer view of a patient's cardiovascular trajectory.
Statins remain the foundation of lipid-lowering treatment. The guidelines recommend lifestyle changes, including diet, exercise, and smoking cessation, as the first step for all patients. But for those at higher risk, doctors are now encouraged to start medication earlier to reduce long-term exposure to elevated cholesterol.
New diagnostic tools are also part of the updated recommendations. A one-time measurement of lipoprotein(a), a genetically determined marker linked to cardiovascular risk, is now recommended for all adults. Coronary artery calcium scoring is suggested for men 40 and older and women 45 and older who fall into borderline or intermediate risk categories.
Treatment targets have also been updated. For primary prevention, the LDL-C goal is below 100 mg/dL for borderline or intermediate risk patients and below 70 mg/dL for high-risk individuals. For patients with existing cardiovascular disease, the target is below 55 mg/dL.
